Ignite Creation Date:
2024-05-05 @ 11:59 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00195039
Status:
COMPLETED
Last Update Posted:
2017-10-05
First Post:
2005-09-14
Brief Title:
Treatment With Radiolabeled Monoclonal Antibody HuJ591-GS 177Lu-J591 in Patients With Metastatic Prostate Cancer
Sponsor:
Weill Medical College of Cornell University
Organization:
Weill Medical College of Cornell University
Study Overview
Official Title:
A Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591-GS 177Lu-J591 in Patients With Metastatic Androgen-Independent Prostate Cancer
Status:
COMPLETED
Status Verified Date:
2017-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to find out how effective 177Lu -J591 is in the treatment of patients with metastatic androgen-independent prostate cancer
Detailed Description:
To determine the clinical activity of 177Lu -J591 for the treatment of patients with metastatic androgen-independent prostate cancer
Patients will receive a single dose of J591 total antibody of 20 mg consisting of antibody chelated with 177Lu at a dose of 65 or 70 mCim2 with a specific activity of 12-15 mCimg plus non-radiolabeled antibody
Patients will receive a single dose of J591 total antibody of 20 mg consisting of antibody chelated with 177Lu at a dose of 65 or 70 mCim2 with a specific activity of 12-15 mCimg plus non-radiolabeled antibody
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 0304006100 | None | None | None |